Breaking News
June 18, 2018 - AHA: Family Perseveres After Losing Father to Heart Attack
June 18, 2018 - Oral propranolol seems safe for infantile hemangioma
June 18, 2018 - New study gives explanation for food’s prominence in memory
June 18, 2018 - First photoactive drug to fight Parkinson’s disease
June 18, 2018 - Patient’s self-evaluation of personality disorders not as far off as previously perceived
June 18, 2018 - Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
June 18, 2018 - Vitamin B3 has a positive effect on damaged nerve cells in Parkinson’s patients
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
Monthly News Roundup – December 2017

Monthly News Roundup – December 2017

image_pdfDownload PDFimage_print

Luxturna Gene Therapy OK’d for Rare Form of Vision Loss

A historic approval, Luxturna (voretigene neparvovec-rzyl) from Spark Therapeutics is the first directly administered gene therapy that targets a disease caused by specific gene mutations. In December the U.S. Food and Drug Administration (FDA) approved Luxturna, used in patients with biallelic RPE65-mediated inherited retinal disease (IRD), a form of vision loss that can lead to blindness. Luxturna is an adeno-associated viral (AAV) vector gene therapy given by subretinal Injection to directly deliver a normal copy of the RPEE65 gene. In a Phase III study, patients had significant improvements in completing an obstacle course at low light levels as compared to the control group.

FDA Clears Giapreza for Dangerous Low Blood Pressure

The FDA has approved Giapreza (angiotensin II) for intravenous infusion to increase blood pressure in adults with septic or other distributive shock. Giapreza, from La Jolla Pharmaceutical, is a synthetic human angiotensin II vasoconstrictor. In studies of 321 patients with shock and a critically low blood pressure, significantly more patients responded to treatment with Giapreza compared to placebo. Giapreza increased blood pressure when added to conventional treatments (fluids and vasopressor therapy such as catecholamines and/or vasopressin) also used to raise blood pressure. Giapreza can cause dangerous blood clots with serious consequences; prophylactic treatment for blood clots should be used.

Rhopressa Approved for Open-Angle Glaucoma or Ocular Hypertension

Glaucoma is often caused by an abnormally high pressure in the eye due to fluid build-up that can damage the optic nerve and lead to blindness. The FDA has now approved Rhopressa (netarsudil ophthalmic solution) once daily eye drops to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. From Aerie Pharmaceuticals, Rhopressa is a Rho kinase inhibitor, and reduces IOP by increasing the outflow of aqueous humor (the fluid inside the eye). Rhopressa is expected to be available on the market in the second quarter of 2018.

Novo Nordisk Gains FDA Approval of Ozempic for Type 2 Diabetes

Type 2 diabetes affects more than 28 million people in the U.S. In response, the FDA has approved Novo Nordisk’s Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes. Ozempic is approved for use in two doses, 0.5 mg and 1 mg, and will be launched in the Ozempic pre-filled pen. In Phase 3 studies, Ozempic showed significant reductions in A1c compared with placebo, sitagliptin (Januvia) and exenatide extended-release (Bydureon); weight loss was also seen. The most common side effects include nausea, vomiting, diarrhea, abdominal pain and constipation.

FDA Approves Three Ertugliflozin-Containing Medicines for Type 2 Diabetes

Patients with type 2 diabetes often need a combination of medications to control their blood sugar. This month, the FDA approved Pfizer and Merck’s new SGLT2 inhibitor Steglatro (ertugliflozin), as well as two new combination agents that contain ertugliflozin: Segluromet (ertugliflozin with the biguanide metformin), and Steglujan (ertugliflozin with the dipeptidyl peptidase-4 inhibitor sitagliptin). In Phase 3 studies, Steglatro was studied as monotherapy (alone) and in combination with metformin and/or sitagliptin, as well as with insulin and a sulfonylurea. Steglatro on top of metformin plus sitagliptin resulted in significant A1C reductions of 0.7% and 0.8% compared with 0.2% for placebo, and weight loss of roughly 6.2 to 6.6 pounds.

Posted: December 2017

Tagged with:

About author

Related Articles